EUVIMEDEUVIMED entdecken
Crossref

Safety and diagnostic performance of endoscopic ultrasound-guided fine needle biopsy in pancreatic cystic and mixed lesions

Nada El-Domiaty, Rita Bou-Farah, Valerie Laurent, Christophe Bellanger, Isabelle Boytchev, Antoine Martin

World Journal of Gastrointestinal Endoscopy · 16.08.2026 · 18 (8)

DOI: 10.4253/wjge.124171 ↗

Kurz gefasst

Fachartikel in der Zeitschrift World Journal of Gastrointestinal Endoscopy, online erschienen am 16.08.2026. Verfasst von Nada El-Domiaty und 5 weiteren Autor:innen. Die Arbeit nennt 28 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND Mixed pancreatic cystic lesions (PCLs) could be a sign of malignant transformation from PCLs. The proper diagnosis of these lesions are crucial for management and avoiding unnecessary treatment. Endoscopic ultrasound (EUS)-guided fine needle biopsy (FNB) may improve diagnostic yield by providing histologic core tissue as well as liquid fraction samples; however, data on its safety and diagnostic performance in cystic and mixed lesions remain limited. AIM To evaluate the safety and diagnostic performance of EUS-FNB using a 22G needle in mixed PCLs. METHODS This retrospective observational cohort study was conducted at a tertiary referral center between January 2019 and December 2024. Consecutive patients undergoing EUS-FNB (22G) for pancreatic cystic or mixed lesions were included. Solid lesions and pancreatic pseudocysts were excluded. Primary outcome was procedure-related safety. Secondary outcomes included technical success, adequacy, diagnostic yield, pathological spectrum, and concordance with surgical histopathology when available. Follow-up data were collected to assess subsequent management and outcomes. RESULTS Among 640 EUS-guided biopsies performed during the study period, 60 patients (mean age 65.0 ± 12.1 years; 36.6% female) underwent EUS-FNB for pancreatic cystic (31.7%) or mixed lesions (68.3%). Technical success was achieved in all cases. Adequate tissue, cytology, or fluid for analysis was obtained in 57 patients (95.0%). No EUS-FNB-related adverse events were observed after review of the medical records. The most frequent diagnosis was pancreatic adenocarcinoma (40.0%), followed by serous cystadenoma (10.0%) and intraductal papillary mucinous neoplasm (10.0%). Overall diagnostic yield was 85.0%. Ten patients underwent surgical resection, with complete concordance between EUS-FNB and surgical histopathology in this selected subgroup. Over a mean follow-up of 17.0 ± 14.3 months, management included chemotherapy, surgery, surveillance, repeat EUS, or drainage according to diagnosis and multidisciplinary assessment. CONCLUSION EUS-FNB using a 22G needle could be a feasible approach for tissue acquisition in pancreatic cystic and mixed lesions, with high technical success and specimen adequacy in this retrospective cohort. Higher quality studies are needed to further define its clinical role and safety profile.

Zitieren

APA

El-Domiaty, N., Bou-Farah, R., Laurent, V., Bellanger, C., Boytchev, I., & Martin, A. (2026). Safety and diagnostic performance of endoscopic ultrasound-guided fine needle biopsy in pancreatic cystic and mixed lesions. World Journal of Gastrointestinal Endoscopy, 18(8). https://doi.org/10.4253/wjge.124171

Vancouver

El-Domiaty N, Bou-Farah R, Laurent V, Bellanger C, Boytchev I, Martin A. Safety and diagnostic performance of endoscopic ultrasound-guided fine needle biopsy in pancreatic cystic and mixed lesions. World Journal of Gastrointestinal Endoscopy. 2026;18(8). doi:10.4253/wjge.124171

BibTeX
@article{ElDomiaty2026,
  author = {El-Domiaty, Nada and Bou-Farah, Rita and Laurent, Valerie and Bellanger, Christophe and Boytchev, Isabelle and Martin, Antoine},
  title = {Safety and diagnostic performance of endoscopic ultrasound-guided fine needle biopsy in pancreatic cystic and mixed lesions},
  journal = {World Journal of Gastrointestinal Endoscopy},
  year = {2026},
  volume = {18},
  number = {8},
  doi = {10.4253/wjge.124171}
}
Kostenlos starten →